Affiliate disclosure: This article contains affiliate links. If you buy through a link on this page, we may earn a commission paid by the manufacturer, at no extra cost to you. That never changes what we publish — and here it should change how you read: we sell both of these products, so this comparison earns nothing by steering you to the dearer one. The honest headline is in the title. Incontinix and Confitrol24 are two packages built on the same patented bladder blend, sold by the same maker — one to men, one to women. What differs is everything around the blend: the dose a buyer can verify, the price, how the trial is reported, and who the product is actually for. If you are deciding between them, the blend is not the decision. This page is.
Quick Answer: Which One Is Yours?
Buy the one made for you — that part really is that simple. Men: Incontinix (Our Score 7.5/10), $59.99, with a published dose of 2 capsules daily delivering 840 mg of the Urox® blend. Women: Confitrol24 (Our Score 8.0/10), $49.00, whose maker reports the same blend's trial but — oddly — never prints the dose on its product page. The blend inside both is identical in kind: Urox®, a proprietary mix of Crateva nurvala (Cratevox™), Lindera aggregata and horsetail, licensed from Seipel Group of Australia. The score gap between the two products is not about formula quality; it is about paperwork — price, dose disclosure and how each maker's page handles the same trial. The details follow, but nobody should cross-buy: a man gains nothing from the women's package, and a woman is not better served by the men's.
| Incontinix (men) | Confitrol24 (women) | |
| Our Score | 7.5/10 | 8.0/10 |
| Price | $59.99 (MSRP $69.99) | $49.00 (MSRP $59.00) |
| Active formula | Urox® blend: Crateva nurvala, Lindera aggregata, horsetail | Urox® blend: same three actives |
| Dose | Published: 2 capsules each morning, 840 mg of blend; 60 capsules per bottle | Not stated on the product page; the maker's wholesale material describes the trial regimen as 2 capsules daily |
| Trial (maker-reported) | 8 weeks, double-blind, placebo-controlled, 150 volunteers, BMC Complementary Medicine and Therapies | 8 weeks, double-blind, placebo-controlled, 150 participants, run at the University of Queensland |
| Guarantee | 67 days | 67 days |
| Positioning | Men: urgency, frequency, night waking, leaks | Women: urge and stress incontinence, accidents, pad use |
The Blend: Genuinely the Same
Urox® is a patented proprietary blend owned by Seipel Group Pty Ltd of Australia and licensed into both products; Leading Edge Health — the maker behind both packages — is listed on the Incontinix label as distributor. The three actives are the same three: Crateva nurvala (in its branded Cratevox™ form), positioned at bladder tone and capacity; Lindera aggregata, positioned at age-related bladder function; and horsetail, positioned at connective-tissue and anti-inflammatory support. In both products the blend is proprietary: per-ingredient amounts are published for neither, so no component dose can be dose-checked in either bottle. One asymmetry worth registering: the Incontinix label publishes the total — 840 mg of blend per daily serving — while the Confitrol24 product page publishes no blend weight at all. Same blend, same silence about its internals, but the men's package tells you one more number than the women's.
The Trial: One Study, Two Write-Ups
Both products lean on a single trial of the Urox® blend, reported by the maker in both cases: eight weeks, double-blind, placebo-controlled, 150 participants. The write-ups differ by package. On the Incontinix side, the maker reports outcomes in percentages — overall urgency reduced by 62%, leaks cut in half, 60% back to normal daytime frequency, about 25% no longer racing to the bathroom at night, 23% totally symptom-free — and names the journal, BMC Complementary Medicine and Therapies, without naming a research site. On the Confitrol24 side, the maker names a site — the University of Queensland — and reports the outcomes in sufferer terms: average daytime frequency returned to normal (under eight times a day), nighttime waking halved, pad use fell significantly, in some cases to zero. Both accounts carry the same core limits, and we apply them evenly: the trial's sponsor is published for neither product, no full citation appears, and everything reaches us through the maker. The Incontinix pages additionally claim the formula "was tested in 14 clinical trials" while describing exactly one; that inflation belongs to the men's marketing and is one reason its credibility marks sit lower. Read both as the maker's report of a real-structured trial of the shared blend — the strongest evidence tier in this category, held by both products equally.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is educational and is not medical advice.
Where They Actually Differ
Dose disclosure. Incontinix tells the buyer exactly what to take: 2 capsules each morning, 60 vegetarian capsules per bottle, a 30-day supply — plus a label-only suggestion to double the dose for the first month, which the marketing never mentions and which halves the bottle's life to 15 days. Confitrol24's product page never states a dose at all; the 2-capsules-daily regimen surfaces only in the maker's wholesale material about the trial. A buyer of the women's product has to leave the product page to learn how to take it. Point to Incontinix.
Price. Confitrol24 is $49.00 a bottle (MSRP $59.00), or 4 interest-free payments of $12.25. Incontinix is $59.99 (MSRP $69.99), or 4 payments of $15.00. Neither maker publishes multi-pack totals as text on its pages; Incontinix has no pack larger than three bottles at all. For the same blend, the women's entry price is eleven dollars lower. Point to Confitrol24.
The guarantee fit. Identical terms — 67 days, empty containers returnable — against an identical eight-week evidence clock. The two-bottle trial course fits inside the window for both products, but only just, and only if you start promptly after delivery. A dead heat, with the same warning attached to both: your refund window opens on delivery day, not on the day you get around to starting.
Safety paperwork. Neither maker publishes warnings, side-effect lists or exclusions for either product — a gap that matters for both sexes, in a category whose buyers commonly take prescription medication. The Incontinix label at least carries generic consult-your-practitioner boilerplate. Dead heat, and not a proud one.
Why the Scores Differ, Then
Confitrol24's 8.0 against Incontinix's 7.5 is a paperwork verdict, not a formula verdict. The women's product scores higher on value (same blend, $11 less) and on its evidence presentation (a named institution, outcomes described without the "14 trials" inflation). The men's product scores back on disclosure (a published dose and blend weight the women's page lacks) and carries the maker's sloppier marketing — typo-ridden store copy, an unnamed doctor endorsement, and the doubled-first-month label line its marketing hides. If the maker fixed either page, the gap would move; the blend would not. Our sub-scores for both are on their product pages — Incontinix and Confitrol24 — for anyone who wants the arithmetic.
The Verdict
This is the rare comparison where the recommendation is a sorting rule, not a winner. Men with the bladder pattern — urgency, frequency, night waking, a normal stream — buy Incontinix, and judge it at eight weeks against the guarantee. Women buy Confitrol24, at the lower price, with the same judging rule. Men whose pattern is really the prostate — weak stream, incomplete emptying — should buy neither: read our prostate, bladder or production explainer and, if it fits, PrimeGENIX Prostate Support. Two packages, one blend — and the only wrong choice is the other sex's box, or any box bought before the pattern check.
Last reviewed: October 2026
